Sigma Pharmaceuticals Ltd
(ASX:SIP) has received a new offer from Aspen Pharmacare.
Following a review of Sigma’s books, Aspen’s new offer of $0.55 cash per Sigma share values the company at $648 million.
The revised offer is 8% lower than its initial offer of $0.60 per Sigma share.
Sigma has advised its shareholders to take no action while it considers this latest offer.
Sigma reported a loss of $389 million for the year ending 30 January 2010.
